/ CASE STUDY
RiverVest led the Series A investment in Standard Bariatrics in 2018. The surgical device company was acquired by Teleflex in 2022 for $170 million plus additional milestone payments.
/ CASE STUDIES
We passionately believe in the companies we fund and commit ourselves to transforming promising technologies into successful therapies.
/ CASE STUDY
Mirum was founded upon a drug compound that RiverVest helped develop through Lumena, a Fund II company acquired in 2014. After the acquirer deprioritized the drug, the Lumena team bought it back so they could finish what they started — getting kids with rare liver disease the relief they need.
/ CASE STUDY
RiverVest co-founded and seed funded Lumena and built a clinical strategy to fast-track its lead drug compound through clinical trials. The company was acquired by Shire in 2014.
RiverVest’s Footprint Increases Its Opportunity Set
RiverVest strives to improve the lives of patients, support entrepreneurs, and earn the trust of investors through science, strategy, and innovation.
Contact us at info@rivervest.com
Transparency in Coverage Rule: To access the machine-readable files created and published by United Healthcare, please click here.
© Copyright 2023 RiverVest® All Rights Reserved. | Privacy Policy
Subscribe to our newsletter